Can afatinib treat lung squamous cell carcinoma? How effective is it?

Lung squamous cell carcinoma is an important subtype of non-small cell lung cancer (NSCLC) and is often closely related to smoking. The treatment of lung squamous cell carcinoma is challenging, especially for patients who are EGFR mutation-negative or who are refractory to other targeted therapies. Afatinib As a second-generation EGFR inhibitor, it mainly targets EGFR mutant lung cancer, but its efficacy in the treatment of lung squamous cell carcinoma has also gradually attracted attention.

The efficacy of afatinib inEGFR mutation-positive patients has been fully verified, but its application in patients with lung squamous cell carcinoma is relatively rare. Lung squamous cell carcinoma is usually EGFR mutation-negative or has a low mutation rate, which limits the efficacy of afatinib. However, some studies have shown that afatinib can also exert a certain therapeutic effect in patients with EGFR mutation-negative lung squamous cell carcinoma.

Afatinib may play a role in some patients with lung squamous cell carcinoma by broadly inhibiting multiple receptors, includingEGFR, HER2 and HER4. Although lung squamous cell carcinoma has fewer EGFR mutations, the abnormal expression of receptors such as HER2 may become another target of afatinib. Therefore, afatinib may still be effective in some patients with lung squamous cell carcinoma, especially if the tumor cells have specific mutations or receptor abnormalities.

However, the use of afatinib in the treatment of lung squamous cell carcinoma remains controversial. Most patients with lung squamous cell carcinoma do not respond as well to EGFR inhibitors as patients with lung adenocarcinoma, which may be due to the different biological characteristics of lung squamous cell carcinoma and lung adenocarcinoma. Despite this, afatinib still has certain therapeutic potential for some patients with lung squamous cell carcinoma, especially when other treatments are ineffective and may become an alternative drug.

In general, afatinib has limited efficacy in the treatment of lung squamous cell carcinoma, and is mainly suitable for patients with EGFR mutation-positive or HER2 abnormalities. For most patients with lung squamous cell carcinoma, the efficacy of afatinib has not been widely recognized, and treatment strategies still need to be selected based on the patient's specific situation and molecular characteristics.

Reference materials:https://www.giotrif.com/